Richard Scott Struthers - 08 May 2024 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
President & CEO, Director
Signature
Marc Wilson, as attorney-in-fact
Issuer symbol
CRNX
Transactions as of
08 May 2024
Net transactions value
-$4,310,814
Form type
4
Filing time
10 May 2024, 16:57:04 UTC
Previous filing
22 Apr 2024
Next filing
04 Dec 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Options Exercise $997,117 +107,448 +42% $9.28 364,933 08 May 2024 Direct
transaction CRNX Common Stock Sale $5,307,931 -107,448 -29% $49.40 257,485 08 May 2024 Direct F1, F2
holding CRNX Common Stock 570,805 08 May 2024 By Family Trust 1
holding CRNX Common Stock 110,000 08 May 2024 By Family Trust 2
holding CRNX Common Stock 110,000 08 May 2024 By Family Trust 3
holding CRNX Common Stock 110,000 08 May 2024 By Family Trust 4
holding CRNX Common Stock 1,000 08 May 2024 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Stock Option (Right to Buy) Options Exercise $0 -107,448 -87% $0.000000 16,342 08 May 2024 Common Stock 107,448 $9.28 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan entered into in March 2023.
F2 The common stock was sold by the reporting person in open market transactions on the transaction date, with a weighted average sales price of $49.40 per share. The range of sales prices on the transaction date was $48.95 to $50.15 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
F3 1/48th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.